GLP Watchdog

Ivy Rx vs Noom

Neither Ivy Rx nor Noom has an FDA warning letter on record. On compounded semaglutide injection, Noom costs $216 less a year at standing rates: $179 a month against $197 a month at Ivy Rx.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Ivy Rx / Noom

Ivy Rx logo

Ivy Rx

7.3/10

Noom logo

Noom

5.8/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$197/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Ivy Rx
Visit Noom

Neither Ivy Rx nor Noom pays us. Links to them earn nothing. Scores: Ivy Rx 7.3, Noom 5.8. How we are paid

What the record shows

  1. 01

    Neither Ivy Rx nor Noom has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded semaglutide injection, Noom costs $216 less a year at standing rates: $179 a month against $197 a month at Ivy Rx.

  4. 04

    Only Ivy Rx lists a price for compounded tirzepatide injection. Only Noom lists a price for brand-name tirzepatide pen.

  5. 05

    Ivy Rx lists all 50 states. Noom publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Ivy Rx

Noom

Compounded semaglutide injection

$197/mo

$2,364 a year

$179/moLower

$2,148 a year

Compounded tirzepatide injection

$297/mo

$3,564 a year

Not sold or not priced
Brand-name tirzepatide pen
Not sold or not priced

$349/mo

$4,188 a year

Price includes
Medication, clinician visits, shipping
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
Not stated
Refunds
All transactions are final; no returns
Refunds only before a prescription is written; renewal charges are not refunded
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Ivy Rx: July 10, 2026. Noom: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Ivy Rx

7.3/10
  • Sells compounded tirzepatide injection, which Noom does not price
  • Names no compounding pharmacy
Visit Ivy Rx

The case for Noom

5.8/10
  • $216 a year less on compounded semaglutide injection
  • Sells brand-name tirzepatide pen, which Ivy Rx does not price
  • Names no compounding pharmacy
  • Publishes no state list
Visit Noom

Scores

Ivy Rx 7.3 · Noom 5.8 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
0.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.5A
vs
B
6.5

Accessibility10%

10.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

Ivy Rx vs Noom: questions

Neither Ivy Rx nor Noom has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Noom, by $216 a year at standing rates. Ivy Rx: $197 a month, about $2,364 a year. Noom: $179 a month, about $2,148 a year.
Ivy Rx states you can cancel at any time; refunds: all transactions are final; no returns. Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded.
Neither Ivy Rx nor Noom pays us. Links to them earn nothing. Scores: Ivy Rx 7.3, Noom 5.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks